Read about the new Rx Products featured in November.
KYLEENAMARKETED BY: Bayer
INDICATION: The FDA has approved Kyleena, a progestin-containing intrauterine system, for the prevention of pregnancy for up to 5 years.
DOSAGE FORM: 1 sterile intrauterine system consisting of a T-shaped polyethylene frame with a steroid reservoir containing 19.5 mg of levonorgestrel
FOR MORE INFORMATION: bayer.us
YOSPRALAMARKETED BY: Aralez Pharmaceuticals
INDICATION: The FDA has approved Yosprala, a once-daily, fixed-dose combination of aspirin and omeprazole for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.
DOSAGE FORM: Tablets: 81 mg of aspirin/40 mg of omeprazole or 325 mg of aspirin/40 mg of omeprazole
FOR MORE INFORMATION: yosprala.com
STELARAMARKETED BY: Janssen
INDICATION: The FDA has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker or who failed or were intolerant to treatment with 1 or more TNF blockers.
DOSAGE FORM: Intravenous infusion: 260, 390, or 520 mg, followed by 90-mg subcutaneous maintenance injections every 8 weeks
FOR MORE INFORMATION: stelarainfo.com
INVOKAMET XRMARKETED BY: Janssen
INDICATION: The FDA has approved Invokamet XR, a once-daily, fixed-dose combination of canagliflozin and metformin hydrochloride extended-release (XR). Invokamet XR is indicated for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes.
DOSAGE FORM: Tablets: 50 or 150 mg of canagliflozin and 500 mg or 1000 mg of metformin XR
FOR MORE INFORMATION: janssen.com